Loading...
About this episode
Dr Khan interviews Dr. Julia Moore-Vogel, Scripps Researcher and lead scientist of the new study using tirzepatide to treat Long COVID. The study is called LoCITT-T, and it is actively enrolling participants. They discuss the study's design, eligibility criteria, and the potential benefits of the drug. Julia shares her personal experience with long COVID and how it has influenced her work. The conversation also covers the importance of making clinical trials accessible to those with disabilities and the innovative use of wearable technology in the study.
Keywords
Long COVID, tirzepatide, clinical trial, disability, wearable technology
Resources:
Long COVID Treatment Trial-Tirzepatide (LoCITT-T): https://www.longcovid.scripps.edu
Fatigue Severity Scale: https://www.med.upenn.edu/cbti/assets/user-content/documents/Fatigue%20Severity%20Scale%20(FSS).pdf
FUN-CAP 27: https://batemanhornecenter.org/wp-content/uploads/2023/12/FUNCAP27-questionnaire.pdf
DSQ-COVID: https://www.researchgate.net/publication/360476212_DePaul_Symptom_Questionnaire-COVID
Eric Topol, MD Ground Truths: https://erictopol.substack.com/
All of Us Research Hub: https://www.researchallofus.org/
Subscribe for free written summaries of each episode, resources, and more. LongCovidMD.substack.com/subscribe
Support by donating at BuyMeACoffee
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
